CompletedPhase 1/2

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

United States165 participantsStarted 2013-12

Plain-language summary

The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HSV-2 seropositive * A minimum of 1 year of reported history of genital herpes and either 2 to 9 recurrences within the year prior to screening or 2 to 9 recurrences per year prior to starting suppressive therapy Exclusion Criteria: * History of receiving an investigational HSV vaccine * Chronic illness for which a subject's immune system is suspected to be impaired or altered, such as cancer, autoimmune conditions, or diabetes * Pregnant or breastfeeding

What they're measuring

Number of participants with adverse events

Timeframe: Up to Day 420

Viral shedding rate change from baseline

Timeframe: Baseline, Day 150

Trial details

NCT IDNCT02030301

SponsorVical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-06

View on ClinicalTrials.gov More Genital Herpes Simplex Type 2 trials